Ashoke Khanwalkar
Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Paranasal Sinuses | 4 | 2023 | 77 | 2.260 |
Why?
| | Nasal Surgical Procedures | 3 | 2023 | 6 | 2.100 |
Why?
| | Rhinitis | 6 | 2025 | 159 | 1.480 |
Why?
| | Tranexamic Acid | 2 | 2023 | 63 | 1.400 |
Why?
| | Endoscopy | 6 | 2026 | 316 | 1.300 |
Why?
| | Sinusitis | 5 | 2025 | 221 | 1.260 |
Why?
| | Lymphatic Abnormalities | 2 | 2020 | 20 | 1.140 |
Why?
| | Nose Diseases | 3 | 2025 | 17 | 1.080 |
Why?
| | Nasal Obstruction | 3 | 2022 | 26 | 1.010 |
Why?
| | Olfaction Disorders | 5 | 2026 | 74 | 0.840 |
Why?
| | Nasal Polyps | 1 | 2024 | 59 | 0.800 |
Why?
| | Telangiectasia, Hereditary Hemorrhagic | 1 | 2022 | 14 | 0.700 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 68 | 0.700 |
Why?
| | Smell | 5 | 2026 | 129 | 0.670 |
Why?
| | Biological Products | 1 | 2024 | 258 | 0.650 |
Why?
| | Cystic Fibrosis | 6 | 2026 | 1164 | 0.620 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 39 | 0.610 |
Why?
| | Neck | 1 | 2020 | 107 | 0.600 |
Why?
| | Hydrocodone | 1 | 2018 | 20 | 0.570 |
Why?
| | Dyspnea | 1 | 2020 | 251 | 0.540 |
Why?
| | Mesothelioma | 2 | 2015 | 50 | 0.530 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.500 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 330 | 0.500 |
Why?
| | Postoperative Complications | 2 | 2020 | 3034 | 0.460 |
Why?
| | Acetaminophen | 1 | 2018 | 268 | 0.460 |
Why?
| | Inpatients | 1 | 2020 | 540 | 0.460 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 344 | 0.450 |
Why?
| | Respiratory Tract Infections | 1 | 2020 | 403 | 0.450 |
Why?
| | Pleural Neoplasms | 1 | 2015 | 31 | 0.440 |
Why?
| | Respiration, Artificial | 1 | 2020 | 711 | 0.430 |
Why?
| | Minimal Clinically Important Difference | 2 | 2026 | 35 | 0.430 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.430 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.430 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 516 | 0.410 |
Why?
| | Epistaxis | 2 | 2023 | 16 | 0.370 |
Why?
| | Turbinates | 2 | 2022 | 14 | 0.340 |
Why?
| | Chronic Disease | 7 | 2026 | 1827 | 0.340 |
Why?
| | Aminophenols | 2 | 2024 | 204 | 0.330 |
Why?
| | Analgesics, Opioid | 1 | 2018 | 1221 | 0.300 |
Why?
| | Quality of Life | 6 | 2026 | 3200 | 0.300 |
Why?
| | Telemedicine | 1 | 2018 | 966 | 0.290 |
Why?
| | Humans | 25 | 2026 | 146342 | 0.240 |
Why?
| | Goldenhar Syndrome | 1 | 2025 | 11 | 0.230 |
Why?
| | Cranial Fossa, Middle | 1 | 2025 | 17 | 0.230 |
Why?
| | Hamartoma | 1 | 2025 | 29 | 0.230 |
Why?
| | Drug Combinations | 3 | 2024 | 400 | 0.220 |
Why?
| | Fistula | 1 | 2025 | 45 | 0.220 |
Why?
| | Benzodioxoles | 2 | 2024 | 164 | 0.220 |
Why?
| | Nasal Cavity | 2 | 2025 | 60 | 0.220 |
Why?
| | Treatment Outcome | 5 | 2024 | 11821 | 0.210 |
Why?
| | Omalizumab | 1 | 2024 | 44 | 0.210 |
Why?
| | Prospective Studies | 8 | 2026 | 8123 | 0.210 |
Why?
| | Intracranial Hypotension | 1 | 2025 | 67 | 0.200 |
Why?
| | Food Preferences | 1 | 2025 | 126 | 0.200 |
Why?
| | Indoles | 2 | 2024 | 511 | 0.190 |
Why?
| | Platelet-Rich Plasma | 1 | 2022 | 44 | 0.180 |
Why?
| | Cautery | 1 | 2022 | 4 | 0.180 |
Why?
| | Blood Loss, Surgical | 1 | 2023 | 117 | 0.180 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2675 | 0.170 |
Why?
| | Vibration | 1 | 2021 | 70 | 0.170 |
Why?
| | Bevacizumab | 1 | 2022 | 169 | 0.170 |
Why?
| | Rhinoplasty | 1 | 2021 | 38 | 0.160 |
Why?
| | Seroma | 1 | 2020 | 3 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 545 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2022 | 253 | 0.140 |
Why?
| | Return to Work | 1 | 2018 | 21 | 0.140 |
Why?
| | Visual Analog Scale | 1 | 2018 | 33 | 0.140 |
Why?
| | Retrospective Studies | 4 | 2025 | 17438 | 0.140 |
Why?
| | Female | 12 | 2026 | 79499 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 992 | 0.130 |
Why?
| | Double-Blind Method | 1 | 2023 | 2070 | 0.130 |
Why?
| | Male | 10 | 2026 | 73396 | 0.130 |
Why?
| | Tumor Burden | 2 | 2015 | 326 | 0.130 |
Why?
| | Operative Time | 1 | 2018 | 195 | 0.130 |
Why?
| | Middle Aged | 8 | 2026 | 36619 | 0.120 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 196 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1763 | 0.100 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2015 | 158 | 0.100 |
Why?
| | Child, Preschool | 2 | 2020 | 11913 | 0.100 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 343 | 0.100 |
Why?
| | Adult | 8 | 2026 | 41087 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2025 | 2786 | 0.090 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 6073 | 0.090 |
Why?
| | Mentors | 1 | 2014 | 217 | 0.090 |
Why?
| | Length of Stay | 1 | 2018 | 1358 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.080 |
Why?
| | Ambulatory Care Facilities | 1 | 2014 | 269 | 0.080 |
Why?
| | Quinolones | 2 | 2024 | 204 | 0.080 |
Why?
| | Education, Medical, Undergraduate | 1 | 2014 | 208 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5439 | 0.080 |
Why?
| | Pyridines | 2 | 2024 | 610 | 0.070 |
Why?
| | Time Factors | 1 | 2020 | 7109 | 0.070 |
Why?
| | Students, Medical | 1 | 2014 | 383 | 0.070 |
Why?
| | Child | 2 | 2020 | 22693 | 0.070 |
Why?
| | Adolescent | 3 | 2026 | 22557 | 0.070 |
Why?
| | Infant | 1 | 2020 | 10114 | 0.060 |
Why?
| | Risk Factors | 1 | 2020 | 10921 | 0.060 |
Why?
| | Ribonuclease III | 1 | 2025 | 44 | 0.060 |
Why?
| | Clinical Competence | 1 | 2014 | 1272 | 0.060 |
Why?
| | Aged | 3 | 2021 | 26432 | 0.050 |
Why?
| | DEAD-box RNA Helicases | 1 | 2025 | 90 | 0.050 |
Why?
| | Young Adult | 3 | 2026 | 14330 | 0.050 |
Why?
| | Pyrrolidines | 1 | 2023 | 127 | 0.050 |
Why?
| | Genetic Testing | 1 | 2025 | 492 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 260 | 0.040 |
Why?
| | Nose | 1 | 2022 | 67 | 0.040 |
Why?
| | Ribs | 1 | 2021 | 35 | 0.040 |
Why?
| | Patient Health Questionnaire | 1 | 2021 | 43 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 380 | 0.040 |
Why?
| | Postoperative Period | 1 | 2021 | 355 | 0.040 |
Why?
| | Cadaver | 1 | 2021 | 304 | 0.040 |
Why?
| | Pyrazoles | 1 | 2023 | 517 | 0.040 |
Why?
| | Cartilage | 1 | 2021 | 198 | 0.040 |
Why?
| | Cost of Illness | 1 | 2022 | 323 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2107 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2021 | 8391 | 0.030 |
Why?
| | Volunteers | 1 | 2014 | 40 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 335 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5899 | 0.020 |
Why?
| | Animals | 1 | 2015 | 38107 | 0.020 |
Why?
| | Peer Group | 1 | 2014 | 251 | 0.020 |
Why?
| | Interpersonal Relations | 1 | 2014 | 387 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1488 | 0.020 |
Why?
| | Program Evaluation | 1 | 2014 | 952 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 2126 | 0.020 |
Why?
|
|
Khanwalkar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|